Every material Form 8-K NEKTAR THERAPEUTICS has filed with the SEC since September 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nektar Therapeutics presented long-term Phase 2b data for rezpegaldesleukin at the EADV 2026 congress, including off-treatment durability in alopecia areata. The filing also says a third Phase 3 atopic dermatitis study has started and a Phase 3 alopecia areata study is planned for early 2027. The filing reports clinical data only, with no revenue, earnings, or guidance figures.
In alopecia areata, 75% (6 of 8) of patients maintained a SALT Score of 20 or less at 4 months off treatment, and 63% (5 of 8) at 6 months.
SALT Score of 10 or less responses rose from 7% at the end of week 52 to 19% after 6 months off treatment.
The Phase 3 ZENITH AA study in alopecia areata is planned to start in early 2027 with 850 patients.
Management hosted a conference call and webcast at 8:00 a.m. ET on October 1, 2026.
Nektar Therapeutics disclosed that a federal jury found Eli Lilly breached the implied covenant of good faith and fair dealing in their license agreement for rezpegaldesleukin. The jury awarded Nektar $90 million in damages plus interest, to be determined by the court. The verdict remains subject to post-trial proceedings and possible appeal, so the amount Nektar ultimately receives is not yet certain.
Jury verdict returned September 24, 2026 in Nektar Therapeutics v. Eli Lilly & Co., Case No. 3:23-cv-03943-JD
Jury awarded Nektar $90 million in damages plus interest, with interest to be set by the District Court
Verdict is subject to post-trial proceedings and any resulting judgment may be appealed
Nektar Therapeutics said it entered a quiet period starting September 8, 2026, until it publicly announces 24-week off-treatment follow-up data from its Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata. The company said the quiet period is consistent with its prior quiet periods for the REZOLVE studies, so the filing signals timing of a future data release rather than results themselves.
Quiet period began September 8, 2026 and runs until the data announcement.
Data to be disclosed is from the 24-week off-treatment follow-up of the Phase 2b REZOLVE-AA study.
Study covers rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
Company says the quiet period matches its earlier REZOLVE study practices.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NEKTAR THERAPEUTICS filing is on SEC EDGAR ↗. 8-K briefs of other companies →